A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens.
Grant Data
Project Title
A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens.
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Lam Chi Leung David
(Co-Investigator)
Dr Wang Kwan Ling Julie
(Co-Investigator)
Dr Lam Chung Mei Jamie
(Co-Investigator)
Dr Wong King Yan Matthew
(Co-Investigator)
Duration
30
Start Date
2009-08-14
Amount
354319
Conference Title
A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens.
Presentation Title
Keywords
Non-small cell lung cancer, Sorafenib
Discipline
Cancer,Respiration
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2009
Status
On-going